Sequencing Immunotherapy in Advanced-Stage Lung Cancer

January 15, 2018
Edward B. Garon, MD

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing immunotherapy agents in advanced-stage lung cancer.<br /> &nbsp;

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing immunotherapy agents in advanced-stage lung cancer.

There had been a lot of debate about the timing of when patients should receive a PD-1 inhibitor, Garon explains.

Results of the KEYNOTE-024 study ended that debate when they showed patients with high levels of staining for PD-L1 were more likely to have an improvement in progression-free survival (PFS) if they received pembrolizumab (Keytruda) over chemotherapy. Additionally, there was a survival advantage seen in patients who received the PD-1 inhibitor as their initial therapy.

There is now a debate once again with the approval of carboplatin, pemetrexed, and pembrolizumab, based on results of the KEYNOTE-021 study.